For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
October 22, 2001
- Abbereviationon of the week
October 22, 2001
- Not to Expect Gov't to Adopt ATP Soon: Mr Butler of PhRMA -1-
October 22, 2001
- Benefits of INNOVA2000 Explained: GE Yokogawa Seminar
October 22, 2001
- Not to Expect Gov't to Adopt ATP Soon: Mr Butler of PhRMA -2-
October 22, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 22, 2001
- Mitsubishi Pharma Establishes Subsidiaries in US, UK
October 22, 2001
- Industry Expresses Opinions on Pricing of Medical Devices: Chuikyo
October 22, 2001
- Losses Reported by 19 of 93 FJPWA Member Wholesalers
October 22, 2001
- GE Marquette Medical Systems: Ultra-small ECG Recorder "SEER Light"
October 22, 2001
- BUSINESS NEWS IN BRIEF -1-
October 22, 2001
- Hac Kimisawa: Half-year Ordinary Profits Up 13.8%
October 22, 2001
- BUSINESS NEWS IN BRIEF -2-
October 22, 2001
- Sugi Yakkyoku: Sales, Profits Up Over 30% in First Half
October 22, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
October 22, 2001
- OTC NEW IN BRIEF
October 22, 2001
- NOTICE
October 22, 2001
- Usefulness of Aspirin Underlined: Dr Hennekens
October 22, 2001
- NHI Price Ceiling to Be Set: Reform Proposal -1-
October 22, 2001
- DIAGNOSTIC NEWS IN BRIEF
October 22, 2001
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…